Get the Stockscreener App
13.96
4.97%
-0.73
After Hours:
13.96
Overview
News
Price History
Option Chain
Financials
Why SLP Down?
Discussions
Forecast
Stock Split
Dividend History
Simulations Plus Inc stock is traded at $13.96, with a volume of 368.58K.
It is down -4.97% in the last 24 hours and up +7.06% over the past month.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
See More
Previous Close:
$14.69
Open:
$14.55
24h Volume:
368.58K
Relative Volume:
1.04
Market Cap:
$282.07M
Revenue:
$80.54M
Net Income/Loss:
$-62.79M
P/E Ratio:
-4.4696
EPS:
-3.1233
Net Cash Flow:
$20.76M
1W Performance:
-11.14%
1M Performance:
+7.06%
6M Performance:
-19.45%
1Y Performance:
-54.70%
1-Day Range:
$13.71
$14.87
1-Week Range:
$13.71
$17.32
52-Week Range:
$11.09
$34.01
Simulations Plus Inc Stock (SLP) Company Profile
Name
Simulations Plus Inc
Sector
Industry
Phone
661-723-7723
Address
800 PARK OFFICES DRIVE, SUITE 401, RESEARCH TRIANGLE PARK, CA
Compare SLP vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLP
Simulations Plus Inc
|
13.96 | 296.82M | 80.54M | -62.79M | 20.76M | -3.1233 |
VEEV
Veeva Systems Inc
|
159.42 | 26.00B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
55.50 | 10.68B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.95 | 8.70B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
80.46 | 6.90B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
26.45 | 4.85B | 637.78M | 239.40M | 307.21M | 1.1909 |
Simulations Plus Inc Stock (SLP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-30-25 | Initiated | TD Cowen | Hold |
| Jul-15-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-15-24 | Initiated | Stephens | Overweight |
| Jul-29-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-16-24 | Initiated | JMP Securities | Mkt Perform |
| Jun-28-24 | Initiated | William Blair | Outperform |
| May-09-23 | Initiated | BTIG Research | Buy |
| Oct-26-21 | Upgrade | Craig Hallum | Hold → Buy |
| Jan-12-21 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-16-20 | Initiated | Raymond James | Outperform |
| Sep-08-20 | Initiated | Oppenheimer | Outperform |
| Jan-06-20 | Initiated | Craig Hallum | Buy |
View All
Simulations Plus Inc Stock (SLP) Latest News
TradingKey - TradingKey
[144] Simulations Plus, Inc. SEC Filing - Stock Titan
Nicholas Company Inc. Buys 78,854 Shares of Simulations Plus, Inc. $SLP - MarketBeat
NVIDIA Pushes AI Into Drug Development With Simulations Plus Collaboration - Yahoo Finance
Simulations Plus unveils method for QST model integration with microphysiological data in liver risk analysis - Traders Union
Simulations Plus, Inc. (SLP): Investor Outlook With A 47% Potential Upside - DirectorsTalk Interviews
SLP Stock Price, Quote & Chart | SIMULATIONS PLUS INC (NASDAQ:SLP) - ChartMill
Simulations Plus (SLP) Partners with NVIDIA for Advanced Drug De - GuruFocus
Simulations Plus teams with NVIDIA on drug modeling - Engineering.com
Simulations Plus (NASDAQ:SLP) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Simulations Plus collaborates with NVIDIA during AI drug modeling push - MSN
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows - HPCwire
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push - Benzinga
Simulations Plus partners with Nvidia on AI drug development By Investing.com - Investing.com India
Simulations Plus partners with Nvidia on AI drug development - Investing.com
Simulations Plus stock surges 28% on NVIDIA collaboration - Investing.com
Simulations Plus And NVIDIA Collaborate To Scale GPU-Accelerated, AI-Assisted Modeling Workflows - marketscreener.com
Insider Sell Alert: DiBella John Anthony II Sells Shares of Simu - GuruFocus
[Form 4] Simulations Plus, Inc. Insider Trading Activity - Stock Titan
Simulations Plus (SLP) insiders sell 15,000 shares in planned trade - Stock Titan
Do options traders know something about Simulations Plus stock we don't? - MSN
(SLP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Do Options Traders Know Something About Simulations Plus Stock We Don't? - Zacks Investment Research
Simulations Plus (SLP) director receives 2,117-share equity grant as compensation - Stock Titan
Director Sharlene Evans receives 2,117 SLP shares in equity grant - Stock Titan
Director at Simulations Plus (SLP) receives 2,117-share stock grant - Stock Titan
Simulations Plus (SLP) director awarded 2,117 shares as equity compensation - Stock Titan
AI in Predictive Toxicology Research Report 2026 Featuring - GlobeNewswire
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance UK
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Latest SLP NewsSimulations Plus Announces Quarterly Cash Di... - Stock Titan
Simulations Plus Q2 2026 earnings preview - MSN
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst - Sahm
(SLP) Risk Channels and Responsive Allocation - Stock Traders Daily
Simulations Plus shares drop over 12% premarket as Q3 revenue forecast misses expectations - MSN
SLP Simulations Plus posts strong Q1 2026 results, shares rise over four percent on double digit EPS and revenue gains.Debt/Equity - Xã Thanh Hà
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com Nigeria
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Simulations Plus enters funded research collaboration with Lonza, FDA - TipRanks
Simulations Plus partners with Lonza and FDA on drug formulation research By Investing.com - Investing.com South Africa
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products - Business Wire
SLP SEC FilingsSimulations Plus Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Simulations Plus (SLP) Completes Successful Spring School Traini - GuruFocus
What Happened to Simulations Plus (SLP) Stock Today (Wavering) 2026-04-20Continuation Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School - 01net
Simulations Plus Inc Stock (SLP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
2.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):